ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of “Buy” by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of “Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $8.00.

A number of research analysts have recently commented on PRQR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Evercore ISI reissued an “outperform” rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, August 8th.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $2.19 on Friday. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The firm’s fifty day moving average price is $2.21 and its two-hundred day moving average price is $1.86. The firm has a market capitalization of $230.41 million, a P/E ratio of -4.76 and a beta of 0.36.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. The firm had revenue of $4.33 million during the quarter, compared to the consensus estimate of $5.01 million. As a group, equities research analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Trading of ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp boosted its holdings in shares of ProQR Therapeutics by 2,550.1% during the 4th quarter. Northern Trust Corp now owns 417,398 shares of the biopharmaceutical company’s stock worth $1,106,000 after buying an additional 401,648 shares during the period. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 12,500 shares during the period. Affinity Asset Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 16.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after buying an additional 459,512 shares during the period. Millennium Management LLC boosted its holdings in shares of ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company’s stock worth $7,492,000 after buying an additional 2,683,351 shares during the period. Finally, Woodline Partners LP bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $9,426,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).